Related Experiment Video
Updated: Jun 6, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
[Effects of finasteride on hematuria associated with benign prostatic hyperplasia: a meta-analysis]
1Department of Urology, Central Hospital of Shaoyang, Shaoyang, Hunan 422000, China. jy3485@sina.com
Insights
Finasteride significantly reduces hematuria in men with benign prostatic hyperplasia (BPH). This study confirms finasteride
Area of Science:
- Urology
- Pharmacology
Context:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- Hematuria is a distressing symptom associated with BPH.
Purpose:
- To systematically evaluate the efficacy of finasteride in managing BPH-associated hematuria.
- To synthesize evidence from randomized controlled trials on finasteride's effect on hematuria.
Summary:
- A systematic review and meta-analysis of randomized controlled trials was conducted.
- Finasteride treatment resulted in a significant reduction in hematuria incidence compared to placebo over 12 months.
- The observed effect was statistically significant (OR 0.11, 95% CI: 0.06-0.21).
Impact:
- Finasteride demonstrates therapeutic and preventive benefits for BPH-related hematuria.
- Findings support finasteride as a treatment option for men experiencing hematuria due to BPH.
- Highlights the need for further large-scale, multicenter trials to solidify these conclusions.
Objective:
To systematically evaluate the effects of finasteride on hematuria associated with benign prostatic hyperplasia (BPH).
Methods:
We electronically searched MEDLINE (December 1966-April 2009), EMBASE (December 1974-April 2009), The Cochrane Library (Issue 1, 2009), CNKI (December 1994-April 2009), VIP (December 1989-April 2009) and CBM (December 1978-April 2009) , and handsearched several relevant journals as well. Randomized controlled trials were assessed with the methods recommended by the Cochrane Collaboration. The data were screened and systematically analyzed by at least two reviewers independently using the RevMan 5.0 software.
Results:
Compared with the placebo control group, the finasteride group showed a significantly decreased incidence of hematuria during the 12 months follow-up period (OR 0.11, 95% CI: 0.06-0.21, P < 0.05).
Conclusion:
Finasteride has desirable therapeutic and preventive effects on BPH-associated hematuria. More well-designed multicentered randomized controlled trials of large sample size are invited to provide further evidence for this conclusion.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Nursing Assessment of the Genitourinary System I: Health History
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Urinary Tract Calculi III: Medical Management
Urodynamic Studies: Uroflowmetry

